$1.04 Billion is the total value of Sofinnova Investments, Inc.'s 164 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 262.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Ishares Nasdaq Biotechnologyput | $27,055,000 | – | 242,000 | +100.0% | 2.61% | – | |
| AGN | New | Allergan plc | $12,981,000 | – | 88,665 | +100.0% | 1.25% | – |
| NVO | New | Novo Nordisk A/Sadr | $12,959,000 | – | 247,734 | +100.0% | 1.25% | – |
| ABBV | New | AbbVie Inccall | $12,089,000 | – | 150,000 | +100.0% | 1.16% | – |
| ALNY | New | Alnylam Pharmaceuticals Inc | $9,964,000 | – | 106,616 | +100.0% | 0.96% | – |
| NBIX | Buy | Neurocrine Biosciences Inc | $9,904,000 | +125.4% | 112,406 | +82.8% | 0.96% | +74.6% |
| BIIB | New | Biogen Inccall | $9,455,000 | – | 40,000 | +100.0% | 0.91% | – |
| MGNX | Buy | MacroGenics Inc | $9,418,000 | +122.8% | 523,756 | +57.3% | 0.91% | +72.3% |
| ANAB | Buy | AnaptysBio Inc | $7,155,000 | +348.6% | 97,948 | +291.5% | 0.69% | +246.7% |
| XNCR | Buy | Xencor Inc | $6,519,000 | -9.7% | 209,907 | +5.1% | 0.63% | -30.2% |
| HALO | New | Halozyme Therapeutics Inc | $6,461,000 | – | 401,329 | +100.0% | 0.62% | – |
| BHVN | Buy | Biohaven Pharmaceutical Holding Company Ltd | $6,432,000 | +78.5% | 124,952 | +28.2% | 0.62% | +38.1% |
| BPMC | New | Blueprint Medicines Corp | $5,753,000 | – | 71,866 | +100.0% | 0.56% | – |
| SVRA | Buy | Savara Inc | $5,651,000 | -1.1% | 766,672 | +1.6% | 0.54% | -23.3% |
| ORTX | Buy | Orchard Therapeutics PLCadr | $4,937,000 | +41.0% | 276,083 | +24.0% | 0.48% | +9.2% |
| KDMN | Buy | Kadmon Holdings Inc | $4,414,000 | +28.5% | 1,671,770 | +1.2% | 0.42% | -0.7% |
| AKBA | New | Akebia Therapeutics Inc | $4,232,000 | – | 516,761 | +100.0% | 0.41% | – |
| INSM | New | Insmed Inc | $4,072,000 | – | 140,057 | +100.0% | 0.39% | – |
| PBYI | New | Puma Biotechnology Inccall | $3,638,000 | – | 93,800 | +100.0% | 0.35% | – |
| XBIT | New | XBiotech Inc | $2,881,000 | – | 261,391 | +100.0% | 0.28% | – |
| TGTX | New | TG Therapeutics Inc | $2,829,000 | – | 351,811 | +100.0% | 0.27% | – |
| New | FibroGen Incput | $2,718,000 | – | 50,000 | +100.0% | 0.26% | – | |
| GLPG | New | Galapagos NVput | $2,355,000 | – | 20,000 | +100.0% | 0.23% | – |
| ARQL | New | ArQule Inc | $1,704,000 | – | 355,725 | +100.0% | 0.16% | – |
| PDSB | New | PDS Biotechnology Corporation | $1,055,000 | – | 142,635 | +100.0% | 0.10% | – |
| PTLA | New | Portola Pharmaceuticals Inc | $1,041,000 | – | 30,000 | +100.0% | 0.10% | – |
| ADVM | New | Adverum Biotechnologies Inc | $835,000 | – | 159,237 | +100.0% | 0.08% | – |
| IMGN | New | ImmunoGen Inccall | $406,000 | – | 150,000 | +100.0% | 0.04% | – |
| CNAT | New | Conatus Pharmaceuticals Inccall | $162,000 | – | 150,000 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.